Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.51 |
| ▸ | HTR2A | P28223 | 14/20 | 0.51 |
| ▸ | HTR2B | P41595 | 13/20 | 0.51 |
| ▸ | PNMT | P11086 | 5/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099113 | 1.00 | HTR2C (0.51) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL5906086 | 0.91 | HTR2C (0.43) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| Succinic Acid SCHEMBL5692284 | 0.90 | HTR2C (0.43) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL12175440 | 0.85 | HTR2C (0.43) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL507491 | 0.84 | HTR2B (0.44) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL15307688 | 0.82 | PNMT (0.33) | PNMT | |
| SCHEMBL10229815 | 0.80 | HTR2A (0.40) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL10277941 | 0.79 | SMN1; SMN2 (0.38) | HTR2CHTR2AHTR2B | |
| Succinic Acid SCHEMBL2369325 | 0.78 | HTR2B (0.39) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL10476312 | 0.77 | HTR2C (0.43) | HTR2CHTR2AHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | claimed |
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| WO-2023278597-A1 | 5-HT2C AGONISTS FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) (US) | 2023-01-05 | — | — | WO | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1924578-B1 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20060264418-A1 | 6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist | ELI LILLY AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| CN-1832926-A | 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | LILLY CO ELI (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1832926-A | 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist | LILLY CO ELI (US) | 2006-09-13 | — | — | CN | disclosed |
| EP-1656352-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO d AZEPINE AS A 5-HT sb 2c /sb RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656352-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO d AZEPINE AS A 5-HT sb 2c /sb RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656352-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO d AZEPINE AS A 5-HT sb 2c /sb RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019180-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019180-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019180-A1 | 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264418-A1 | 6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2A 2/4885HTR2B 11/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2C 1/4885HTR2A 5/4885HTR2B 7/4885 |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ADRA2C, HTR2C, HTR2A | HTR2C 2/4885HTR2A 3/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.